Global and Japan Hydroxychloroquine (Plaquenil) Market Insights, Forecast to 2027

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.2 Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects.6 Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.7It is taken by mouth.[2] It is also being used as an experimental treatment for coronavirus disease 2019 (COVID-19).

Market Analysis and Insights: Global and Japan Hydroxychloroquine (Plaquenil) Market
This report focuses on global and Japan Hydroxychloroquine (Plaquenil) market.
In 2020, the global Hydroxychloroquine (Plaquenil) market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Hydroxychloroquine (Plaquenil) market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Hydroxychloroquine (Plaquenil) Scope and Market Size
Hydroxychloroquine (Plaquenil) market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Hydroxychloroquine (Plaquenil) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Hydroxychloroquine (Plaquenil) market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
100mg
200mg
Other

Segment by Application
Lupus Erythematosus
Rheumatoid Arthritis
COVID-19
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Sanofi
Actavis (TEVA )
Mylan
Novartis
Covis Pharmaceutical
Cardinal Health
Apotex Corporation
Hikma Pharmaceuticals
Aphena Pharma
Concordia Healthcare
AvKARE (Amneal Pharmaceuticals)
Ipca Laboratories
Shanghai Pharmaceuticals Holding
Taj Pharmaceuticals
Cinkate Corporation
Cadila Healthcare
Sun Pharma
Zydus Cadila
Advanz Pharma
Bristol Laboratories
Hanlim Pharmaceutical
Kyung Poong